Gossamer Bio Faces Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy GOSS?
Source: Globenewswire
- Class Action Filed: Bragar Eagel & Squire, P.C. has initiated a class action lawsuit against Gossamer Bio on behalf of investors who purchased securities between June 16, 2025, and February 20, 2026, indicating significant legal challenges for the company.
- False Information Allegations: The lawsuit alleges that Gossamer provided false and misleading information regarding its Phase 3 PROSERA study, leading investors to buy securities at artificially inflated prices, resulting in financial losses.
- Investor Rights Protection: Investors have until June 1, 2026, to apply to be appointed as lead plaintiff, highlighting the legal team's commitment to safeguarding investor rights, which may impact the company's future stock performance.
- Law Firm Credentials: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities and commercial litigation, demonstrating its expertise and influence in investor protection matters.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.329
Low
10.00
Averages
12.33
High
15.00
Current: 0.329
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gossamer Bio Faces Class Action Lawsuit
- Class Action Filed: Bragar Eagel & Squire, P.C. has initiated a class action lawsuit against Gossamer Bio on behalf of investors who purchased securities between June 16, 2025, and February 20, 2026, indicating significant legal challenges for the company.
- False Information Allegations: The lawsuit alleges that Gossamer provided false and misleading information regarding its Phase 3 PROSERA study, leading investors to buy securities at artificially inflated prices, resulting in financial losses.
- Investor Rights Protection: Investors have until June 1, 2026, to apply to be appointed as lead plaintiff, highlighting the legal team's commitment to safeguarding investor rights, which may impact the company's future stock performance.
- Law Firm Credentials: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities and commercial litigation, demonstrating its expertise and influence in investor protection matters.
See More
Gossamer Bio Faces Class Action Lawsuit Over Misleading Trial Results
- Lawsuit Background: Gossamer Bio, Inc. is facing a class action lawsuit in the U.S. District Court for the Southern District of California, representing all investors who purchased its securities between June 16, 2025, and February 20, 2026, alleging the company provided misleading information regarding its Phase 3 PROSERA study.
- Study Results Failure: The complaint highlights that Gossamer's press release on February 23, 2026, revealed that its Phase 3 PROSERA study failed to meet the primary endpoint, with a +13.3 meter improvement in six-minute walk distance that did not achieve the required 0.025 significance level, leading to a loss of investor confidence.
- Stock Price Plummet: Following the announcement of the study results, Gossamer's stock price plummeted from $2.13 per share on February 20, 2026, to $0.42 per share on February 23, 2026, reflecting a staggering decline of over 80% in just one day, indicating severe market concerns about the company's future.
- Investor Action: Affected investors are encouraged to contact the law firm before the June 1, 2026, lead plaintiff motion deadline to represent other shareholders in the litigation and ensure their rights are protected.
See More
Gossamer Bio Faces Shareholder Class Action Lawsuit
- Lawsuit Background: A shareholder class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the company failed to disclose significant adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning the control of placebo responses at Latin American testing sites, which may undermine investor confidence.
- Investor Losses: The lawsuit targets investors who purchased Gossamer Bio shares between June 16, 2025, and February 20, 2026, encouraging those who experienced significant losses during this period to contact legal counsel to understand their rights, highlighting a strong investor concern for corporate transparency.
- Legal Representation: Holzer & Holzer, LLC, a top-rated securities litigation law firm, focuses on vigorously representing shareholders and investors, having recovered hundreds of millions of dollars for defrauded shareholders in recent years, indicating the firm's strength and influence in the legal landscape.
- Lawsuit Deadline: Investors must apply to be appointed lead plaintiff in the case by June 1, 2026, emphasizing the importance of timely action to secure their rights in the litigation process, reflecting the urgency and complexity of legal proceedings.
See More
Pomerantz LLP Investigates Gossamer Bio for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Gossamer Bio investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, highlighting serious concerns over corporate governance.
- Clinical Trial Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA trial for pulmonary arterial hypertension failed to meet its primary endpoint, leading to a significant decline in market confidence regarding its future prospects.
- Stock Price Plunge: Following the trial failure announcement, Gossamer's stock price plummeted by $1.71, a staggering 80.14% drop, closing at $0.423 per share, reflecting extreme investor anxiety about the company's financial health.
- Potential Legal Consequences: This investigation could lead to a class action lawsuit against Gossamer, and if wrongdoing is confirmed, it may have profound implications for the company's reputation and future financing capabilities.
See More
Gossamer Bio Under Investigation as Stock Plummets 80%
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Gossamer Bio, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could expose the company to significant legal risks.
- Clinical Trial Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA trial for pulmonary arterial hypertension failed to meet its primary endpoint, directly impacting investor confidence and raising concerns about the company's drug pipeline.
- Stock Price Plummet: Following the trial results, Gossamer's stock price fell by $1.71, a staggering 80.14% drop, closing at $0.423 per share, reflecting extreme market pessimism regarding the company's future prospects and financial health.
- Potential Legal Consequences: The investigation could lead to a class action lawsuit against Gossamer, and if found guilty of fraud, the company may face severe financial repercussions and reputational damage, prompting investors to closely monitor developments.
See More
Cantor Fitzgerald Downgrades Gossamer Bio Amid Regulatory Uncertainty
- Rating Downgrade: Cantor Fitzgerald has downgraded Gossamer Bio from overweight to neutral due to uncertainty surrounding the regulatory path for seralutinib as a treatment for pulmonary arterial hypertension, indicating a decline in market confidence regarding the drug's future prospects.
- Clinical Trial Disappointment: The topline results from the February PROSERA phase 3 study failed to meet statistical significance, leading analysts to adopt a cautious stance on Gossamer's commercialization potential, although they still acknowledge some compelling data indicating a solid signal for the drug.
- FDA Meeting Request: Gossamer has requested a Type C meeting with the US FDA, expected to take place in June, which should provide clearer guidance on seralutinib's path forward, with potential clarity anticipated in July.
- Market Sentiment: Analyst Olivia Brayer Saunders noted that while Gossamer possesses some compelling data, the lack of strong conviction regarding the commercialization path may impact investor sentiment towards the company's long-term outlook.
See More
Gossamer Bio Faces Class Action Lawsuit
- Class Action Filed: Bragar Eagel & Squire, P.C. has initiated a class action lawsuit against Gossamer Bio on behalf of investors who purchased securities between June 16, 2025, and February 20, 2026, indicating significant legal challenges for the company.
- False Information Allegations: The lawsuit alleges that Gossamer provided false and misleading information regarding its Phase 3 PROSERA study, leading investors to buy securities at artificially inflated prices, resulting in financial losses.
- Investor Rights Protection: Investors have until June 1, 2026, to apply to be appointed as lead plaintiff, highlighting the legal team's commitment to safeguarding investor rights, which may impact the company's future stock performance.
- Law Firm Credentials: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities and commercial litigation, demonstrating its expertise and influence in investor protection matters.
See More
Gossamer Bio Faces Class Action Lawsuit Over Misleading Trial Results
- Lawsuit Background: Gossamer Bio, Inc. is facing a class action lawsuit in the U.S. District Court for the Southern District of California, representing all investors who purchased its securities between June 16, 2025, and February 20, 2026, alleging the company provided misleading information regarding its Phase 3 PROSERA study.
- Study Results Failure: The complaint highlights that Gossamer's press release on February 23, 2026, revealed that its Phase 3 PROSERA study failed to meet the primary endpoint, with a +13.3 meter improvement in six-minute walk distance that did not achieve the required 0.025 significance level, leading to a loss of investor confidence.
- Stock Price Plummet: Following the announcement of the study results, Gossamer's stock price plummeted from $2.13 per share on February 20, 2026, to $0.42 per share on February 23, 2026, reflecting a staggering decline of over 80% in just one day, indicating severe market concerns about the company's future.
- Investor Action: Affected investors are encouraged to contact the law firm before the June 1, 2026, lead plaintiff motion deadline to represent other shareholders in the litigation and ensure their rights are protected.
See More
Gossamer Bio Faces Shareholder Class Action Lawsuit
- Lawsuit Background: A shareholder class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the company failed to disclose significant adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning the control of placebo responses at Latin American testing sites, which may undermine investor confidence.
- Investor Losses: The lawsuit targets investors who purchased Gossamer Bio shares between June 16, 2025, and February 20, 2026, encouraging those who experienced significant losses during this period to contact legal counsel to understand their rights, highlighting a strong investor concern for corporate transparency.
- Legal Representation: Holzer & Holzer, LLC, a top-rated securities litigation law firm, focuses on vigorously representing shareholders and investors, having recovered hundreds of millions of dollars for defrauded shareholders in recent years, indicating the firm's strength and influence in the legal landscape.
- Lawsuit Deadline: Investors must apply to be appointed lead plaintiff in the case by June 1, 2026, emphasizing the importance of timely action to secure their rights in the litigation process, reflecting the urgency and complexity of legal proceedings.
See More
Pomerantz LLP Investigates Gossamer Bio for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Gossamer Bio investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, highlighting serious concerns over corporate governance.
- Clinical Trial Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA trial for pulmonary arterial hypertension failed to meet its primary endpoint, leading to a significant decline in market confidence regarding its future prospects.
- Stock Price Plunge: Following the trial failure announcement, Gossamer's stock price plummeted by $1.71, a staggering 80.14% drop, closing at $0.423 per share, reflecting extreme investor anxiety about the company's financial health.
- Potential Legal Consequences: This investigation could lead to a class action lawsuit against Gossamer, and if wrongdoing is confirmed, it may have profound implications for the company's reputation and future financing capabilities.
See More
Gossamer Bio Under Investigation as Stock Plummets 80%
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Gossamer Bio, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could expose the company to significant legal risks.
- Clinical Trial Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA trial for pulmonary arterial hypertension failed to meet its primary endpoint, directly impacting investor confidence and raising concerns about the company's drug pipeline.
- Stock Price Plummet: Following the trial results, Gossamer's stock price fell by $1.71, a staggering 80.14% drop, closing at $0.423 per share, reflecting extreme market pessimism regarding the company's future prospects and financial health.
- Potential Legal Consequences: The investigation could lead to a class action lawsuit against Gossamer, and if found guilty of fraud, the company may face severe financial repercussions and reputational damage, prompting investors to closely monitor developments.
See More
Cantor Fitzgerald Downgrades Gossamer Bio Amid Regulatory Uncertainty
- Rating Downgrade: Cantor Fitzgerald has downgraded Gossamer Bio from overweight to neutral due to uncertainty surrounding the regulatory path for seralutinib as a treatment for pulmonary arterial hypertension, indicating a decline in market confidence regarding the drug's future prospects.
- Clinical Trial Disappointment: The topline results from the February PROSERA phase 3 study failed to meet statistical significance, leading analysts to adopt a cautious stance on Gossamer's commercialization potential, although they still acknowledge some compelling data indicating a solid signal for the drug.
- FDA Meeting Request: Gossamer has requested a Type C meeting with the US FDA, expected to take place in June, which should provide clearer guidance on seralutinib's path forward, with potential clarity anticipated in July.
- Market Sentiment: Analyst Olivia Brayer Saunders noted that while Gossamer possesses some compelling data, the lack of strong conviction regarding the commercialization path may impact investor sentiment towards the company's long-term outlook.
See More
